Search

Displaying results 8511 - 8520 of 10000 in total
  1. Drug

    Alpha-galactosylceramide

    go.drugbank.com/drugs/DB12232
    Investigational

    KRN7000 has been used in trials studying the treatment of Lung Cancer, Chronic Hepatitis C, Hepatitis B, Chronic, Unspecified Adult Solid Tumor, Protocol Specific, and Prevention of GvHD in Patients With

    Synonyms: 1-O-(α-D-galactopyranosyl)-N-hexacosanoylphytosphingosine
  2. Drug

    Bexagliflozin

    go.drugbank.com/drugs/DB12236
    ApprovedInvestigational

    Bexagliflozin is a highly specific and potent sodium-glucose co-transporter 2 (SGLT2) inhibitor. … [A256408,A256413,L44758] Similar to other SGLT2 inhibitors, bexagliflozin contains three basic moieties: glucose, two benzene rings and a methylene bridge.

    Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesSynonyms: D-glucitol, 1,5-anhydro-1-C-(4-chloro-3-((4-(2-(cyclopropyloxy)ethoxy)phenyl)methyl)phenyl)-, (1s)-, (2S,3R,4R,5S,6R)-2-(4-chloro-3-((4-(2-(cyclopropyloxy)ethoxy)phenyl)methyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
  3. Drug

    TAK-733

    go.drugbank.com/drugs/DB12241
    Investigational

    TAK-733 has been used in trials studying the treatment of Advanced Metastatic Melanoma, Advanced Nonhematologic Malignancies, and Advanced Non-hematologic Malignancies.

    Synonyms: (R)-3-(2,3-DIHYDROXYPROPYL)-6-FLUORO-5-(2-FLUORO-4-IODOPHENYLAMINO)-8-METHYLPYRIDO(2,3-D)PYRIMIDINE-4,7(3H,8H)-DIONE, 3-[(2R)-2,3-dihydroxypropyl]-6-fluoro-5-[(2-fluoro-4-iodophenyl)amino]-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dioneCategories: Heterocyclic Compounds, 1-Ring
  4. Drug

    Tulobuterol

    go.drugbank.com/drugs/DB12248
    Investigational

    Tulobuterol has been used in trials studying the treatment of Chronic Obstructive Pulmonary Disease.

    Categories: Selective Beta 2-adrenergic Agonists
  5. Drug

    Cixutumumab

    go.drugbank.com/drugs/DB12250
    Investigational

    Cixutumumab is a highly specific recombinant human monoclonal antibody with high affinity for the insulin-like growth factor-I receptor (IGF-IR). IGF-IR is overexpressed in a variety of tumour types.

    Categories: Receptor, IGF Type 1
  6. Drug

    Vadadustat

    go.drugbank.com/drugs/DB12255
    ApprovedInvestigational

    These transcription factors serve a multitude of roles, including the stimulation of erythropoiesis. … One of the most common symptoms of advanced renal disease is anemia, caused primarily by the inability of the kidney to respond to anemic conditions with a corresponding increase in [erythropoietin] (EPO

    Categories: Cytochrome P-450 CYP2B6 Inducers, Heterocyclic Compounds, 1-RingSynonyms: Glycine, N-((5-(3-chlorophenyl)-3-hydroxy-2-pyridinyl)carbonyl)-, N-(5-(3-Chlorophenyl)-3-hydroxypyridine-2-carbonyl)glycine
  7. Drug

    Radiprodil

    go.drugbank.com/drugs/DB12260
    Investigational

    Radiprodil has been used in trials studying the treatment of Infantile Spasms (IS) and Diabetic Peripheral Neuropathic Pain.

    Categories: Heterocyclic Compounds, 1-Ring
  8. Drug

    Atevirdine

    go.drugbank.com/drugs/DB12264
    Investigational

    Atevirdine has been used in trials studying the treatment of HIV Infections.

    Categories: Heterocyclic Compounds, 1-Ring
  9. Drug

    Epofolate

    go.drugbank.com/drugs/DB12266
    Investigational

    Epofolate (BMS-753493) is a folate conjugate of the epothilone analog BMS-748285 that was designed to selectively target folate receptor expressing cancer cells. … In Phase I/IIa pharmacokinetic and safety studies epofolate was generally tolerable and toxicities known to be associated with epothilone class of anticancer agents were common, although peripheral neuropathy

    Categories: Cytochrome P-450 CYP3A Inhibitors, Heterocyclic Compounds, 2-Ring
  10. Drug

    Brigatinib

    go.drugbank.com/drugs/DB12267
    ApprovedInvestigational

    [A31311] It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. … Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR).

    Mixtures: ALUNBRİG 90 MG VE 180 MG FİLM KAPLI TABLET TEDAVİYE BAŞLANGIÇ PAKETİ, 7 ADET 90 MG VE 21 ADET 180 MG, ALUNBRİG 90 MG VE 180 MG FİLM KAPLI TABLET TEDAVİYE BAŞLANGIÇ PAKETİ, 7 ADET 90 MG VE 21 ADET 180 MGCategories: Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index